A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)

Trial Profile

A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Cardiomyopathies
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTR-ACT
  • Sponsors FoldRx Pharmaceuticals; Pfizer
  • Most Recent Events

    • 29 Mar 2018 According to a Pfizer Media Release, the company is planning to share the detailed results of the study with the cardiovascular community and discussing these data with health authorities to determine an appropriate regulatory path. The full data and detailed results will be submitted for presentation at an upcoming scientific congress as well as for publication in a peer-reviewed journal.
    • 29 Mar 2018 Preliminary topline data published in the Pfizer Media Release
    • 17 Feb 2018 This trial has been completed in Belgium, (End date: 2018-02-07) according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top